Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07134296

Magnetic Resonance Imaging (MRI)-Guided Rectal Cancer Preservation Program

The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of rectal preservation

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

HYPOTHESIS

The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a TNT Program renders improved TME-free rates due to the better visualization and online dose-adaptation of the Gross Tumor Volume (GTV).

Rationale In the radiation setting, MRI provides superior soft tissue contrast compared to standard onboard X-ray imaging improving inter- and intra- observer delineation variation. MRgRT offers the opportunity to adapt the plan at each fraction to the anatomical changes seen. This is especially important in rectal cancer where the rectum is subject to interfractional position changes, volume shrinkage and intrafractional shape and size variation due to the variability in rectal filling.

Primary Objectives

A. To achieve 3-year TME-free survival of 75% while keeping 3-year DFS rates of 75%.

B. To achieve a CTCAE v5 grade 2-3 proctitis of less than 10% and grade 2-3 rectal bleeding rate of <2% at 2 years.

C. To achieve a Wexner Continence score of at least 90% over baseline at 2 years.

Secondary Objectives

A. Determination of blood and urine biomarkers of treatment response and toxicity .

B. Determination of radiomics biomarkers of treatment response and toxicity . C. Determination of rectal functionality with the Wexner Continence Score.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 or older with primary Stage II (T3-4, N0) or Stage III (any T, N1-2) biopsy-proven rectal cancer
  • No prior radiation therapy to the target areas;
  • ECOG 0-2 with medical status not contraindicating treatment with radical intent including TNT and TME (if required) and with basal laboratory values as follows:
  • Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
  • Platelets ≥ 50,000 cells/mm3.
  • Hemoglobin ≥ 8.0 g/dl.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 4 x upper limit of normal.
  • Total bilirubin < 2 x upper normal mg/dL.
  • Alkaline phosphatase < 4 x upper limit of normal.

Exclusion criteria

  • Patient unable to undergo an MRI examination

Treatment and study plan

MR-guided Irradiation

Radiation

MR-Guided Irradiation

Primary outcomes

  1. Total Mesorectal Excision (TME)-free survival

    Time frame: 5-years

    To achieve 3-year TME-free survival of 75% while keeping 3-year DFS rates of 75%.

Secondary outcomes

  1. Proctitis/Rectal Bleeding

    Time frame: 5-years

    To achieve a CTCAE v5 grade 2-3 proctitis of less than 10% and grade 2-3 rectal bleeding rate of <2% at 2 years.

  2. Fecal Continence

    Time frame: 5-years

    To achieve a Wexner Continence score of at least 90% over baseline at 2 years.

Study contacts

Contact information is provided by the study sponsor or research team.

Beatriz Ramos Aguirre, M.S.

CONTACT

[email protected]

+34 948255400 ext. 2772

Sponsors and collaborators

Lead sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Other

Registry information

Official study title

MRI-guided Rectal Cancer Preservation Program

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Aug 21, 2025
Registry last updated
Aug 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.